Growth Metrics

RedHill Biopharma (RDHL) Gross Profit (2016 - 2023)

Historic Gross Profit for RedHill Biopharma (RDHL) over the last 9 years, with Q2 2023 value amounting to $990000.0.

  • RedHill Biopharma's Gross Profit fell 8941.29% to $990000.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $15.3 million, marking a year-over-year decrease of 5115.57%. This contributed to the annual value of $4851.0 billion for FY2024, which is 15796147603.39% up from last year.
  • Latest data reveals that RedHill Biopharma reported Gross Profit of $990000.0 as of Q2 2023, which was down 8941.29% from $2.0 million recorded in Q1 2023.
  • In the past 5 years, RedHill Biopharma's Gross Profit ranged from a high of $12.4 million in Q3 2021 and a low of -$659000.0 during Q1 2020
  • Moreover, its 5-year median value for Gross Profit was $5.5 million (2020), whereas its average is $5.5 million.
  • In the last 5 years, RedHill Biopharma's Gross Profit plummeted by 14992.42% in 2020 and then skyrocketed by 166631.26% in 2021.
  • Quarter analysis of 5 years shows RedHill Biopharma's Gross Profit stood at $802000.0 in 2019, then skyrocketed by 1247.76% to $10.8 million in 2020, then plummeted by 74.68% to $2.7 million in 2021, then surged by 53.45% to $4.2 million in 2022, then crashed by 76.43% to $990000.0 in 2023.
  • Its Gross Profit was $990000.0 in Q2 2023, compared to $2.0 million in Q1 2023 and $4.2 million in Q4 2022.